ConductScience.org, home

Paper42818643PubMed

Chemical Genetic Targeting of the LRRK2 GTPase Domain.

Prorok RE and 6 others. bioRxiv, 2026.

Cite this record

ConductScience Library. Chemical Genetic Targeting of the LRRK2 GTPase Domain. Papers, record 42818643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42818643

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chemical Genetic Targeting of the LRRK2 GTPase Domain.
Journal
bioRxiv
Year
2026
Publication types
Journal Article, Preprint
Revised in PubMed
2026-10-09

Source PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
F31 CA301949NCI NIH HHSUnited StatesF31CA301949PubMedNIH RePORTER
F31 NS122434NINDS NIH HHSUnited StatesF31NS122434PubMedNIH RePORTER

Download CSV of grants

References59

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132250617Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.J Med Chem2020https://conductscience.org/library/papers/32250617PubMed
223241358GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.Hum Mol Genet2013https://conductscience.org/library/papers/23241358PubMed
337339170A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.Cancer Res2023https://conductscience.org/library/papers/37339170PubMed
426407721MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.J Pharmacol Exp Ther2015https://conductscience.org/library/papers/26407721PubMed
528918051LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.Mol Ther Nucleic Acids2017https://conductscience.org/library/papers/28918051PubMed
631658955The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer Discov2020https://conductscience.org/library/papers/31658955PubMed
734088839Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/34088839PubMed
833997272SMALL MOLECULE IMAGING AGENT FOR MUTANT KRAS G12C.Adv Ther (Weinh)2021https://conductscience.org/library/papers/33997272PubMed
930609797Roco Proteins: GTPases with a Baroque Structure and Mechanism.Int J Mol Sci2019https://conductscience.org/library/papers/30609797PubMed
1025317655Revisiting the Roco G-protein cycle.Biochem J2015https://conductscience.org/library/papers/25317655PubMed
1138039358Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.Sci Adv2023https://conductscience.org/library/papers/38039358PubMed
124076451414-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state.Nat Commun2025https://conductscience.org/library/papers/40764514PubMed
1334515301Impact of Type II LRRK2 inhibitors on signaling and mitophagy.Biochem J2021https://conductscience.org/library/papers/34515301PubMed
1435950872Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.Biochem J2022https://conductscience.org/library/papers/35950872PubMed
1535675433Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.Sci Transl Med2022https://conductscience.org/library/papers/35675433PubMed
162406906Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins.Science1990https://conductscience.org/library/papers/2406906PubMed
1714654223Roc, a Ras/GTPase domain in complex proteins.Biochim Biophys Acta2003https://conductscience.org/library/papers/14654223PubMed
1834471232The KRAS-G12C inhibitor: activity and resistance.Cancer Gene Ther2022https://conductscience.org/library/papers/34471232PubMed
1939642212Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C.Cancer Discov2025https://conductscience.org/library/papers/39642212PubMed
2039255801Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket.Cell2024https://conductscience.org/library/papers/39255801PubMed

See all 59 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
LRRK2120892PubTator's text mininghttps://conductscience.org/library/genes/120892NCBI Gene
RAB1010890PubTator's text mininghttps://conductscience.org/library/genes/10890NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42818643

GET https://conductscience.org/api/papers/v1/42818643/references?page=2